Positron emission tomography/magnetic resonance imaging with 68Gallium-labeled ligand of prostate-specific membrane antigen: Promising novel option in prostate cancer imaging?

International Journal of Urology

Volumn 21, Issue 12, 2014, Pages 1286-1288

  Maurer, Tobias ^a   Beer, Ambros J ^a   Wester, Hans Jürgen ^a   Kübler, Hubert ^a   Schwaiger, Markus ^a   Eiber, Matthias ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GALLIUM 68; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN LIGAND GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; GADOLINIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CASE REPORT; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; WHOLE BODY MRI; DIAGNOSTIC IMAGING; DIAGNOSTIC USE; DIFFERENTIAL DIAGNOSIS; METABOLISM; PROCEDURES; PROSTATIC NEOPLASMS;

AGED; ANTIGENS, SURFACE; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; GADOLINIUM; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS;

EID: 84925341230     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12577     Document Type: Article

References (7)

1. Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur. Urol. 2013; 64: 106-117.
2. Schafer M, Bauder-Wust U, Leotta K etal. A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res. 2012; 2: 23.
3. Afshar-Oromieh A, Haberkorn U, Eder M, Eisenhut M, Zechmann CM. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur. J. Nucl. Med. Mol. Imaging 2012; 39: 1085-1086.
4. Roethke MC, Kuru TH, Afshar-Oromieh A, Schlemmer HP, Hadaschik BA, Fenchel M. Hybrid positron emission tomography-magnetic resonance imaging with gallium 68 prostate-specific membrane antigen tracer: a next step for imaging of recurrent prostate cancer-preliminary results. Eur. Urol. 2013; 64: 862-864.
5. Drzezga A, Souvatzoglou M, Eiber M etal. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J. Nucl. Med. 2012; 53: 845-855.
6. Arce-Calisaya P, Souvatzoglou M, Eiber M etal. Sensitivity of PET/MRI to detect recurrence of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 2013; 40: 799.
7. Kuru TH, Roethke MC, Seidenader J etal. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J. Urol. 2013; 190: 1380-1386.